Floatz logo

T-CELL SURFACE ANTIGEN T4/LEU-3

Sarcoma

M.D. Anderson Cancer Centerprotein_peptidePhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Roswell Park Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

T-CELL SURFACE ANTIGEN T4/LEU-3 is also rated in:

T-cell non-Hodgkin lymphomaDormant
C
Indicative ·
36 / 100
View asset →
plasma cell myelomaDormant
D
Indicative ·
30 / 100
View asset →
graft versus host diseaseDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →